Abstract Details

Title Application of electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-001

Objective

To assess muscle impedance parameters as potential biomarker of inclusion body myositis (IBM).

Background

There is an unmet need for an objective, easily applicable biomarker to assess IBM disease severity. Electrical impedance myography (EIM), a noninvasive technique, has shown promise as a potential biomarker in some neuromuscular disorders. This pilot study is evaluating the potential of EIM as a biomarker of IBM (clinicaltrials.gov || NCT03633318).

Design/Methods We intend to recruit 20 patients with clinicopathologically confirmed IBM and age-matched healthy controls. We present a preliminary analysis of 5 IBM patients (4 men, 1 woman; age 66 ± 6 years) enrolled since August 2018. Healthy control data are not yet available. Each participant went through manual muscle testing (MMT) in neck flexion/extension, and 15 extremity muscles on both sides (maximum MRC score of 160), 6-minute walk (6MW), hand-grip dynamometry, IBM-functional rating scale (IBM-FRS), and EIM measurements of deltoid, biceps, forearm flexors, rectus femoris, tibialis anterior, and medial gastrocnemius. Spearman rank correlation was used.

Results

Mean ± SD of MMT, grip strength (kg; Right/Left), IBM-FRS, 6MW (feet) were 130.75 ± 15, 9.8 ± 5/8.4 ± 5.4, 28.6 ± 7, and 1187 ± 480 respectively. Strong correlation was noted between averaged EIM-50 kHz and averaged ratio of EIM 200 kHz/50 kHz (EIM-200/50) from six muscles with IBM-FRS and 6MW distance (absolute rho ≥ 0.9, p-value ≤0.001). Hand grip strength showed moderate correlation with EIM-50 kHz from forearm muscles (rho 0.66, p-value 0.037). At individual muscle level, moderate correlation was noted between EIM-50 kHz, EIM-200/50 and the weak muscles; rho values 0.58, -0.59 respectively with p-values<0.001.

Conclusions

Preliminary results suggest that EIM can be a potential IBM biomarker. However, these results should be interpreted carefully given the small sample size and further validation studies required. Our study remains open to enrollment with additional data available for presentation forthcoming.

Authors/Disclosures
Bhaskar Roy, MD, FAAN (Yale University) PRESENTER	Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Roy has stock in Cabaletta bio. . Dr. Roy has stock in Pfizer. Dr. Roy has stock in CAVA. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals. The institution of Dr. Roy has received research support from Immunovant. The institution of Dr. Roy has received research support from argenx.
Seward B. Rutkove, MD, FAAN	Dr. Rutkove has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Myolex, Inc. Dr. Rutkove has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neuorlogy . The institution of Dr. Rutkove has received research support from NIH. The institution of Dr. Rutkove has received research support from NASA. The institution of Dr. Rutkove has received research support from Blavatnik Family Foundation. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.
Richard J. Nowak, MD (Yale University School of Medicine)	Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio . Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cour Pharma. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janseen . The institution of Dr. Nowak has received research support from UCB. The institution of Dr. Nowak has received research support from Alexion . The institution of Dr. Nowak has received research support from Janseen. The institution of Dr. Nowak has received research support from Immunovant . The institution of Dr. Nowak has received research support from argenx. The institution of Dr. Nowak has received research support from Amgen. Dr. Nowak has a non-compensated relationship as a Member of the Board of Directors with Myasthenia Gravis Foundation of America (MGFA) that is relevant to AAN interests or activities.

��ɫ��

��ɫ��